DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Jan Stahlberg Acquires 40,253 Shares of Stock

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) major shareholder Jan Stahlberg bought 40,253 shares of the stock in a transaction dated Monday, November 24th. The shares were purchased at an average price of $7.89 per share, for a total transaction of $317,596.17. Following the purchase, the insider owned 8,752,643 shares of the company’s stock, valued at $69,058,353.27. This trade represents a 0.46% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Jan Stahlberg also recently made the following trade(s):

• On Tuesday, November 25th, Jan Stahlberg purchased 73,099 shares of DiaMedica Therapeutics stock. The stock was purchased at an average price of $8.57 per share, with a total value of $626,458.43.
• On Friday, November 21st, Jan Stahlberg acquired 208,872 shares of DiaMedica Therapeutics stock. The shares were purchased at an average price of $7.41 per share, for a total transaction of $1,547,741.52.
• On Thursday, November 20th, Jan Stahlberg bought 128,426 shares of DiaMedica Therapeutics stock. The shares were purchased at an average cost of $7.41 per share, with a total value of $951,636.66.
• On Wednesday, November 19th, Jan Stahlberg bought 240,352 shares of DiaMedica Therapeutics stock. The stock was acquired at an average cost of $7.21 per share, with a total value of $1,732,937.92.
• On Tuesday, November 18th, Jan Stahlberg purchased 182,882 shares of DiaMedica Therapeutics stock. The stock was acquired at an average price of $6.75 per share, for a total transaction of $1,234,453.50.
• On Monday, November 17th, Jan Stahlberg acquired 187,393 shares of DiaMedica Therapeutics stock. The stock was acquired at an average price of $6.52 per share, with a total value of $1,221,802.36.

DiaMedica Therapeutics Stock Down 0.2%

NASDAQ DMAC opened at $8.76 on Tuesday. The firm has a 50-day moving average price of $7.15 and a two-hundred day moving average price of $5.73. DiaMedica Therapeutics, Inc. has a 12-month low of $3.19 and a 12-month high of $9.23. The company has a market capitalization of $456.22 million, a P/E ratio of -12.34 and a beta of 1.31.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Equities analysts expect that DiaMedica Therapeutics, Inc. will post -0.59 EPS for the current year.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new position in DiaMedica Therapeutics in the third quarter valued at about $27,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of DiaMedica Therapeutics in the second quarter valued at approximately $29,000. Bank of America Corp DE raised its holdings in DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after buying an additional 8,274 shares during the last quarter. JPMorgan Chase & Co. bought a new position in DiaMedica Therapeutics in the 2nd quarter valued at approximately $49,000. Finally, Invesco Ltd. acquired a new stake in DiaMedica Therapeutics during the 2nd quarter worth approximately $54,000. Institutional investors own 10.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on DMAC shares. Cowen began coverage on DiaMedica Therapeutics in a research note on Thursday, October 30th. They set a “buy” rating on the stock. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a research report on Friday, August 15th. Cantor Fitzgerald started coverage on DiaMedica Therapeutics in a research note on Friday, November 14th. They issued an “overweight” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.